Sector News

Gilead’s huge Sovaldi payoff yields a nice 23% pay hike for CEO

March 31, 2015
Life sciences
No one would say Gilead Sciences CEO John Martin is hurting financially. For several years, he has collected annual compensation worth about $15 million. Not too shabby. And his stock gains since 2009 run into the hundreds of millions–yes, hundreds.
 
But for a record-smashing year that vaulted his company into the ranks of the global top 10, Martin snared a comparatively small payoff.
 
True, Martin’s 2014 compensation grew by $3.5 million, to almost $19 million. That’s a 23% increase. His base salary amounted to $1.6 million, his options were worth $5.2 million, and his stock awards hit $8.4 million. Cash incentive pay was an impressive $3.72 million.
 
Plus, according to Gilead’s proxy statement, the payoff from stock options he exercised last year was more than $158 million. Again, who’d feel sorry for a guy with that kind of compensation package? Certainly not the patient advocates who protest Gilead’s aggressively high prices.
 
But for a biotech CEO with a record-smashing year, that $18.5 million is, well, conservative. For the most obvious example, look at Regeneron. When the company’s blockbuster eye drug Eylea hit the market by storm in 2012, CEO Len Schliefer collected $26.6 million worth of options and $30 million in total pay. R&D chief George Yancopoulos scored an even bigger sum; his 2012 compensation amounted to $81.5 million. That’s including $21 million in options, plus a $57 million retention grant aimed at keeping him in place through 2017.
 
Or United Therapeutics, which gave CEO Martine Rothblatt a $36 million equity award in 2013, ostensibly to bring her compensation up to par with that of her peers. No big-time launch that year, no major payoff for shareholders–but the board decided the company’s ongoing performance, compared with that of its rivals, was strong enough to put Rothblatt in the 75th percentile, compensation-wise.
 
Or Valeant Pharmaceuticals, which handed CEO J. Michael Pearson $12.2 million in stock awards for his M&A-fueled growth record–and that was for 2011, before Valeant bought Medicis, Bausch & Lomb, or Obagi. That year, he also got a $13.9 million dividend agreed on in 2008, back when Valeant and Biovail merged. His total for 2011? More than $36 million.
 
Or Allergan, the company Valeant tried to buy until Actavis swooped in with a higher offer. CEO David Pyott got a “one-time special” share award in 2012, worth $9.4 million at the time. The extra boost recognized Pyott for boosting the company’s market value by $30 billion since taking over the CEO chair–and because it wouldn’t vest till 2017, was a retention bonus, too. Under the terms of its merger with Actavis, Allergan will accelerate vesting of its share awards–including Pyott’s.
 
We are not arguing for Gilead to give Martin and his execs a major windfall. His $3.5 million raise for 2015 simply illustrates how one company’s compensation committee can make wildly different decisions from another’s, and both say they emphasize compensation that rewards CEOs and their colleagues for performance. Some are mavericks. Others, not so much. To be fair, most pharma companies don’t hand out big, one-time share awards.
 
So, executive pay may purportedly follow some rhyme and reason, but that all depends on who’s dictating the rhyme scheme. And frankly, put all these top-earning CEOs in the EU, and shareholders would be marching in the streets.
 
By Tracy Staton
 

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach